News

News stories

Dementia patient

New clue in understanding increased Alzheimer’s risk

Scientists have discovered a new piece of the puzzle in understanding why some people are more susceptible to Alzheimer’s disease.
Pam Shaw in front of SITraN

Comment: A devastating setback for MND research: Why NICE needs to reconsider its approach to tofersen

Professor Dame Pamela Shaw, Director of the 91̽»¨ Institute for Translational Neuroscience, discusses NICE's refusal to classify the MND drug tofersen, as a treatment for a highly specialised condition, rather than just a standard drug.
Image of motor neurones

91̽»¨ team is sole UK recipient to be awarded share of $5 million global funding to fight motor neuron disease

A team of researchers from the University of 91̽»¨ have been awarded a share of a prestigious grant to fight MND.
A young MND patient being cared for by their mum

New psychological therapy shows promise in improving quality of life for people living with MND

Therapy can significantly improve quality of life for people living with MND when delivered alongside usual care, a pioneering study led by the University of 91̽»¨ has shown.
DNA Molecule

University of 91̽»¨ spinout company to pioneer novel therapies for genetic neurological diseases

BlackfinBio has raised £2.75 million seed investment to advance revolutionary treatments for Hereditary Spastic Paraplegia (HSP).

The Duchess of Gloucester visits SITraN

The Duchess of Gloucester explores pioneering Parkinson's research at SITraN

Parkinson’s UK Patron, Her Royal Highness The Duchess of Gloucester, met neuroscientists from the University of 91̽»¨ who are tackling the root causes of the progressive condition 
Image of motor neurones

New research institute to accelerate the search for a cure for MND

The new UK Motor Neuron Disease Research Institute, or UK MND RI, aims to discover new treatments that could ultimately mean MND becomes a curable condition.
Neuron cells system - 3d rendered image of Neuron cell network on black background

University of 91̽»¨ spinout company Crucible Therapeutics raises £5 million to advance pioneering treatments for neurological diseases

University of 91̽»¨ spinout company, Crucible Therapeutics, a biotechnology company developing novel therapies to treat the most common genetic form of MND and frontotemporal dementia (FTD), has secured £5 million from Northern Gritstone.
Dr Dan Blackburn from the University of 91̽»¨ introducing a study participant to the CognoSpeak system on a laptop

AI tool could speed up dementia diagnosis

A new AI tool that could help doctors assess the early signs of dementia and Alzheimer’s more quickly and efficiently, has been developed by researchers at the University of 91̽»¨.